Serek-N
Nimesulide 100 mg + Paracetamol 325 mg + Serratiopeptidase 15 mg
Clinical Differentiators & Advantages
PCD Franchise Distribution
Verify if exclusive marketing and distribution rights for Serek-N are currently vacant in your target district.
Active Chemical Compounds & Molecular Architecture
Validated chemical entities, 2D skeletal bond diagrams, empirical molecular formulas, and receptor-level modes of action
Preferential COX-2 inhibitor with rapid onset and cartilage-protective properties.
Centrally acts to elevate pain threshold and bring down fever.
Fibrinolytic enzyme accelerating hematoma and inflammatory exudate drainage.
Approved Clinical Indications & Disease Burden
Pharmacodynamic Mechanism of Action
Nimesulide is a preferential COX-2 inhibitor with rapid 15-minute onset that scavenges free radicals and inhibits chondrocyte apoptosis; Paracetamol boosts central antipyretic synergy; Serratiopeptidase rapidly clears inflammatory edema.
Dosage & Administration Protocol
1 tablet twice daily after food for short-term pain relief (max 15 days).
Precautions, Warnings & Contraindications
B2B Commercial & Shipping Metrics
Moisture-sealed 5-ply export corrugation
Includes visual aids & promotional inputs
Private label & institutional supply
Standard pharmaceutical commercial tariff
Certificate of Analysis (COA), Stability Study Reports (Zone IVb), Finished Product Specs (FPS), and Material Safety Data Sheet (MSDS).
Frequently Prescribed & Stocked Together
Clinically aligned formulations commonly co-prescribed with Serek-N to improve patient outcomes and expand distributor portfolio basket size.
APAR / APAR-S / APAR-MR Range
Aceclofenac + Paracetamol (± Serratiopeptidase / Thiocolchicoside)
“Super Speed, Super Power & Prompt Relief — Powerful Yet Safer”
CT-Flam
Trypsin 48 mg + Bromelain 90 mg + Rutoside Trihydrate 100 mg + Aceclofenac 100 mg
“Reduce Oedema with CT-Flam — Cut Down Suffering Softly”
Serek-D
Diclofenac Potassium 50 mg + Serratiopeptidase 10 mg
“Dual Action Rapid Pain Relief & Enzyme Penetration”